A Study to Assess The Amyotrophic Lateral Sclerosis (ALS) Patient Experience


About this study

The purpose of this study is to support and extend the results of the FORTITUDE-ALS clinical trial, a clinical trial of an investigational drug (reldesemtiv) for the treatment of amyotrophic lateral sclerosis (ALS).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • English-speaking participants.
  • Reside in the US.
  • Completed FORTITUDE-ALS clinical trial.
  • Consent to be interviewed at the completion of the study.

Exclusion Criteria:

  • Non-English speaking participants.
  • Not a U.S. resident.
  • Did not complete FORTITUDE-ALS clinical trial.
  • Does not consent to be interviewed at the completion of the study.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Jacksonville, Fla.

Mayo Clinic principal investigator

Bjorn Oskarsson, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer